LIHIT LAB., INC.

As of August 31, 2024, LIHIT LAB., INC. carries a market capitalization of 3.84B, placing it among publicly traded companies globally. Its enterprise value stands at 2.91B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

LIHIT LAB., INC.'s next confirmed earnings release is scheduled for January 1, 2027.

As of August 31, 2024, LIHIT LAB., INC. has 3.39M shares outstanding.

These figures are as of August 31, 2024. The price-to-sales ratio is 0.43, and the price-to-book ratio stands at 0.37.

These figures are as of August 31, 2024. The EV/Sales ratio of 0.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.91B versus a market cap of 3.84B, with the gap driven by net debt and cash on the balance sheet.

As of August 31, 2024, LIHIT LAB., INC. maintains a current ratio of 5.01, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.79, indicating elevated leverage, while an interest coverage ratio of -16.52 demonstrates limited ability to service its debt obligations.

Over the twelve months ended August 31, 2024, LIHIT LAB., INC. posted a negative return on equity (ROE) of -0.46, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.36, reflecting losses generated across the asset base. The company generates approximately 15.23M in revenue per employee across its workforce of 593.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.57 indicates how many times LIHIT LAB., INC. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended August 31, 2024, LIHIT LAB., INC. recorded an income tax benefit of -18.09M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -65.19M and -47.10M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, LIHIT LAB., INC.'s stock has declined approximately 1.19% over the past 52 weeks. The 50-day moving average sits at 1,156.88, while the 200-day moving average is 1,171.58.

Over the twelve months ended August 31, 2024, LIHIT LAB., INC. generated 9.03B in revenue and converted that into -47.10M in net income, yielding earnings per share of -13.88. EBITDA reached -109.32M, while operating income came in at -109.32M.

As of August 31, 2024, LIHIT LAB., INC. holds 1.53B in cash and equivalents against 594.50M in total debt, resulting in a net debt position of -932.66M. Total book value stands at 10.27B, with working capital of 4.52B providing operational flexibility.

Over the twelve months ended August 31, 2024, LIHIT LAB., INC. posted a gross margin of 30.12, reflecting its pricing power and cost economics. The operating margin of -1.21 and net profit margin of -0.52 provide insight into operational efficiency.

LIHIT LAB., INC.'s most recent stock split took place on November 29, 2021 with a 1:2 split ratio.

As of August 31, 2024, LIHIT LAB., INC. has an Altman Z-Score of 2.61, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.